Previous 10 | Next 10 |
home / stock / alpmy / alpmy news
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th...
Quick Take Aptinyx ( APTX ) intends to sell 5.33 million shares of common stock at a midpoint price of $15.00 per share for gross proceeds of approximately $80 million, according to an amended registration statement . The company is advancing a promising pipeline of small molecule treatm...
Recently, Vical Incorporated ( VICL ) announced its results from a phase 2 study treating patients with the herpes simplex virus type 2 ((HSV-2)). It announced that the trial had failed , and thus the stock had traded lower by 29% pre-market. It still has another product in the pipeline it ...
TOKYO and BOTHELL, Wash. , June 3, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the presentation of updated phase 1 data of enfortumab vedotin, an i...
TOKYO , May 31, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced the launch of the third annual Astellas Oncology C 3 Prize (Changing Cancer Care), a global challenge aimed at inspiring non-treatment ideas ...
Analysis Focus: CPRX Catalyst Pharmaceuticals (CPRX) is a smallcap company with $363M in market capitalization. The company was founded as Catalyst Pharmaceutical Partners, Inc. in 2002 and is based in Coral Gables, Florida. Their focus is on development and commercialization of therapies ...
The FDA accepts under Priority Review Astellas Pharma's ( OTCPK:ALPMF )( OTCPK:ALPMY ) marketing application seeking approval for gilteritinib for the treatment of adult patients with relapsed/refractory FLT3-positive acute myeloid leukemia (AML). The agency's action date is November ...
TOKYO , May 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company's New Drug Application (NDA) for gilteritinib for t...
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
The following slide deck was published by Astellas Pharma, Inc. ADR in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer PR Newswire - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted...
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire - If approved, enfortumab vedotin in combination with pembrolizumab ...
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy PR Newswire - Collaborative Research on Innovative Cartilage Organoid Cell Therapy for In...